Erasca (ERAS) Net Income Growth (3y) (2023 - 2026)

Erasca (ERAS) Net Income Growth (3y) (2023 - 2026) Analysis & Trends

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Income Growth (3y) (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	6.30%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	10.23%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	72.22%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	37.89%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	25.99%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-38.56%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	37.44%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	62.15%
10	Erasca	6.43 Bn	6.16 Bn	-	-92.10%

Download Data